Trial Profile
Bioequivalence study of OPC-41061 1% powder-formulation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Tolvaptan
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 14 Jun 2016 New trial record